GlassScriptPhysician profile
Hugh Stoddard
NPI 1215374251
$524.69
in general payments reported to CMS, 2019-2025
12 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.75 · 2022: $37.91 · 2023: $136 · 2024: $162 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106.85 | 2022-2024 | Taltz, Ebglyss |
| Abbvie INC. | $74.56 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $73.46 | 2022-2025 | Winlevi, Absorica Ld |
| Novo Nordisk INC | $64.05 | 2023-2025 | Ozempic, Rybelsus |
| Janssen Biotech, INC. | $63.37 | 2023-2024 | Remicade, Stelara, Simponi Aria |
| Ucb, INC. | $27.22 | 2025 | Bimzelx |
| Genzyme Corporation | $23.52 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.18 | 2024 | Spevigo |
| Almirall LLC | $21.17 | 2025 | Seysara |
| Stemline Therapeutics INC. | $16.75 | 2019 | |
| Amgen INC. | $16.38 | 2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.18 | 2024 | Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Stoddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.